{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-24-000029","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2024-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.268078+00:00","generated_at":"2026-06-03T13:39:00.276051+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neurogene Reports Positive Initial Safety Data from Phase 1/2 Gene Therapy Trial for Rett Syndrome","bullets":["NGN-401 generally well-tolerated in three patients with multiple months of follow-up.","No treatment-emergent or procedure-related serious adverse events or MeCP2 overexpression toxicity observed.","Data presented at ASGCT Annual Meeting; includes one patient with mild variant predicted to retain residual MeCP2 function.","Company expects interim efficacy readout in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-24-000029","json":"https://secwatch.observer/filing/0001404644-24-000029.json","markdown":"https://secwatch.observer/filing/0001404644-24-000029.md","text":"https://secwatch.observer/filing/0001404644-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000029/0001404644-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000029/ngne-20240422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T13:39:00.276051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}